clinical trial · NCT07170150
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Hoffmann-La Roche·phase3·recruiting·n = 800
Alzheimers DiseaseTrontinemabPlacebo
brief summary
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
started
Nov 12, 2025
primary completion
Jun 7, 2028
completion
Jun 7, 2028
last updated
Apr 13, 2026
official title
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol